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Computationally-Guided Optimization of Small-Molecule 
Inhibitors of the Aurora A Kinase – TPX2 Protein-Protein 
Interaction  
Daniel J. Cole,a,b,† Matej Janecek,c,d Jamie E. Stokes,d Maxim Rossmann,e John C. Faver,a      
Grahame J. McKenzie,c Ashok R. Venkitaraman,c Marko Hyvönen,e David R. Spring,d                  
David J. Huggins,c,d,f and William L. Jorgensena 
Free energy perturbation theory, in combination with enhanced 
sampling of protein-ligand binding modes, is evaluated in the 
context of fragment-based drug design, and used to design two new 
small-molecule inhibitors of the Aurora A kinase – TPX2 protein-
protein interaction. 
 
Aurora A is one of three human aurora kinases, a family of 
serine/threonine kinases that play a central role in cell division.1 
Aurora A and Aurora B are critical for mitotic cell division, in which 
Aurora C is also implicated2 alongside its role in meiosis.3 During 
mitosis, Aurora A associates with the centrosome and the spindle 
microtubules to control centrosome maturation and spindle 
assembly.4 It acts in part through direct phosphorylation of partners 
such as PLK1.5 Aurora A is ubiquitously expressed but its expression 
is strongly cell cycle dependent. Its expression peaks at the G2-M 
transition, when it is involved in the mitotic checkpoint.6 Aurora A is 
a 403-residue protein, composed of an N-terminal domain, a protein 
kinase domain, and a C-terminal domain. The N-terminal and C-
terminal domains contain a KEN degradation motif and a destruction 
box (D-box) respectively, both of which control degradation.7 
Aurora A is oncogenic and is overexpressed in tumors of the breast, 
colon, stomach, and ovaries.8 Inhibition of Aurora A leads to cell 
death in dividing cells, through a mechanism involving chromosome 
misalignment and stalling at the mitotic checkpoint.9,10 As a 
consequence, it has received a lot of attention as a potential drug 
target in cancer7 and numerous kinase inhibitors have been 
described.11-13 A number of these inhibitors are now in clinical 
trials.11 As well as the ATP-binding site, an additional allosteric 
binding site can also be targeted to modulate Aurora A function.14 
During mitosis, Aurora A is localized to microtubules in the mitotic 
spindle through an interaction between the kinase domain and the 
protein TPX2.15 The N-terminal sequence of TPX2 binds to an 
allosteric pocket on Aurora A16 and stimulates kinase activity, leading 
to cell-cycle progression. Interruption of the Aurora A - TPX2 
interaction reduces kinase activity, leading to mislocalization of 
Aurora A, mitotic defects, and cell cycle arrest.17 
In previous work, some of us have described the development of 
small-molecule inhibitors targeting the TPX2 binding pocket of 
Aurora A.18 In particular, through a process of high-throughput 
screening of diverse chemical libraries19 and fragment 
deconstruction, the fragment 2-phenyl-4-carboxyquinoline 
(compound 1, Figure 1) was developed. Compound 1 shows a dose-
dependent inhibition of TPX2 binding to Aurora A in a fluorescence 
anisotropy (FA) assay (Ki = 63 μM). A process of synthesis and 
investigation of structure-activity relationship (SAR) trends was 
embarked upon to improve the potency of the fragment, mainly 
through increasing the hydrophobicity of the phenyl group which 
occupies the pocket formed by residues L178, V182, V206 and L208 
(Figure 1). The most potent molecule, named AurkinA (Ki = 2.7 μM), 
was shown to inhibit the kinase activity of Aurora A in vitro and 
mislocalize Aurora A from mitotic spindle microtubules in vivo.18 
AurkinA provides a blueprint for future design efforts that target the 
TPX2 binding pocket of Aurora A. 
Free energy perturbation (FEP) theory for the computation of 
relative binding free energies is a promising companion for the 
fragment-based drug discovery (FBDD) techniques used above (see 
the ESI). In FBDD, improvement of the binding affinity is the most 
important factor and multiple rounds of synthesis are often required 
to obtain the requisite potency gains.20 However, for fragments that 
bind with mM to high μM affinity it is often difficult to accurately 
measure binding constants in biological assays and hence pursue 
SAR. These technical problems should not affect the accuracy of FEP 
methods and hence efficiency gains in the FBDD process are expected 
if X-ray crystallography and computational predictions are used in 
tandem. A recent study of the binding of 90 small molecules to a 
range of targets revealed that FEP is able to predict relative binding 
affinities in FBDD studies with root mean square (RMS) errors of 
approximately 1.1 kcal/mol.21 
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The MCPRO software22 is a widely used tool for quantitative 
predictions of relative binding free energies, which uses FEP theory 
in combination with Monte Carlo sampling (MC/FEP). Notable 
successes include the prediction of a number of extremely potent 
inhibitors of HIV reverse transcriptase23 and macrophage migration 
inhibitory factor.24 However, it has not been used before now to our 
knowledge in FBDD efforts. A potential hurdle to its uptake is the 
possibility of a range of dynamic binding modes that are available to 
small, flexible fragments. In the current study for example the 
flexibility of the phenyl-quinoline linker (Figure 1) means that groups 
added to the phenyl ring may orient either toward or away from the 
hydrophobic floor of the binding pocket. Furthermore, as we shall 
show, the addition of the bulky groups to the ligand may induce re-
orientation of the L178 side chain, in a manner reminiscent of the 
V111 side chain rotation in the T4 lysozyme model system, which has 
been shown to be problematic for standard FEP simulations.25 
In what follows, we describe the application of MCPRO, in 
combination with the recently implemented replica exchange with 
solute tempering (REST) enhanced sampling method,26-29 to the 
study of the relative affinities of 14 small molecule inhibitors of 
Aurora A. The REST algorithm has been shown to substantially 
improve the consistency of MC/FEP results by improving 
conformational sampling, thereby reducing dependency on the 
choice of starting structure.28 The computed conformational 
ensembles have additionally been shown to be in excellent 
agreement with molecular dynamics simulations.29 Here, the REST 
method successfully incorporates torsional sampling of both the 
phenyl group and L178 side chain in a single simulation and 
recapitulates the experimental binding data in the majority of cases. 
In addition, we make two new experimentally-verified predictions, 
one of which yields a small molecule inhibitor that is equally potent 
as AurkinA. This study points to the potential for routine use of 
MC/FEP in prospective fragment-based lead optimization. 
Optimization of the binding potency of small molecule analogs of 
compound 1 was initially pursued by investigating substituents at the 
meta and para positions of the phenyl ring (see the ESI). The 
asymmetric substitutions pose a problem for traditional FEP 
simulations, since the simulation firstly needs to find the preferred 
binding pose (e.g. Figure 2(a,b)), which is not necessarily known a 
priori, and secondly needs to account for the entropic penalty 
associated with the loss of symmetric binding modes.30 The REST 
algorithm implemented in MCPRO accounts for both of these factors 
by effectively enhancing the sampling of dihedral angle 'flips' 
between alternative binding modes.28 
In addition, our crystallographic data are inconclusive concerning 
which of the two rotamers of L178 shown in Figure 2(a,c) is preferred 
for a given substituent. Previous crystallographic studies of the T4 
lysozyme hydrophobic cavity have shown that the size of the binding 
pocket is strongly influenced by the size of the bound ligand31 and 
computational estimates of binding affinity can be strongly 
dependent on the choice of starting structure.25,32 Here, initial 
estimates of the binding free energy of a Cl substituent at the meta 
position, relative to F, gave -0.27 kcal/mol starting from the structure 
shown in Figure 2(a) and -0.78 kcal/mol starting from the structure in 
Figure 2(c). We have therefore added the residue L178 to the REST 
enhanced sampling region and allowed flips in the angle χ during our 
simulations (Figure 1). The computed binding free energy of Cl, 
relative to F, is then independent of the choice of starting structure 
(-0.73 and -0.80 kcal/mol respectively). 
Table 1 shows the comparisons between computation (including 
both the ligand and residue L178 in the REST region) and 
experimental FA assays.18 In general, it can be seen that adding 
halogens at the position X is predicted to be favorable. In particular, 
with the enhanced sampling of L178, the prediction Br > F > H is in 
line with experimental results. X = Cl is actually predicted to be more 
potent than X = Br, but compound 4 has not been synthesized. The 
additional substitution of Z = F is also found to enhance binding 
relative to Z = H. 
To demonstrate the conformational sampling facilitated by the 
REST method, Figure 3 shows the distribution of dihedral angles in 
simulations of 2 and 5 bound to Aurora A. Compound 2 samples all 
of the conformations shown in Figure 2 with a preference for φ = 330o 
and χ = 180o (Figure 2(b)). In contrast, binding of 5 with the bulkier Cl 
in the meta position leads to a reorientation of the L178 side chain (χ 
= 60o). There is a slight preference for Cl to be oriented toward the 
hydrophobic floor of the binding pocket (χ = 180o) but both 
conformations of the phenyl group are sampled. In order to check the 
orientation of the small molecules in the binding pocket, we have 
collected X-ray crystal structures of 2 and 5 (see the ESI). In contrast 
to the MC simulations, both crystal structures clearly show that φ is 
close to 180o. The discrepancy is possibly due to force field 
inaccuracy, crystallization conditions, or a small population of 
alternative conformations may not be visible in the X-ray electron 
density. It is more difficult to assign the orientation of the L178 side 
chain, and so the inter-conversion between the two populations 
observed in the MC simulations may be accurate. 
Returning to the prediction of relative binding free energies, the 
substitution of bulky methyl and trifluoromethyl at the meta position 
was predicted to be less favorable than compound 1, although 7 
showed reasonable activity experimentally (Table 1). On the basis of 
the computational data 8 was not pursued further. Interestingly, 
however, there does appear to be space to accommodate a methyl 
substitution in the TPX2 pocket at the para position on the phenyl 
ring. In particular, compounds 9 and 10 show enhanced activity in FEP 
simulations relative to 2 and 6, respectively. As a result of these 
predictions, compounds 9 and 10 were synthesized and assayed (see 
the ESI), resulting in the most potent fragment reported here 
(compound 10, Ki = 2.3 μM). As predicted, compound 9 also shows 
enhanced activity relative to 2. 
Encouraged by these results, we tested four more compounds 
with potential benefits (Figure 4). Compound 11 introduces an 
electronegative N atom into the TPX2 binding pocket, but this is 
predicted to be unfavorable. This result is in qualitative agreement 
with the SAR presented in Ref. 18 for a set of related molecules. 
Compound 12 was expected to orient the ligand for optimal binding 
in the Aurora A binding pocket. However, the relative binding free 
energy was predicted to be similar to 6 and so was not pursued 
further. As a further test of the FEP methodology, the relative binding 
free energy of AurkinA (compound 13) was computed. In agreement 
with experiment, the F substituent on the quinoline was extremely 
favorable. A similar substitution on compound 10 may improve its 
potency still further. Finally, compound 14 showed good predicted 
activity but could not be synthesized so far. 
As a means of benchmarking computational methodologies, it is 
commonplace to compare computed ΔΔG with experimental 
pIC50.21,30 Figure 5 compares the computed and experimental results 
where available. The mean unsigned error is 0.24 kcal/mol, the root-
mean-square error is 0.32 kcal/mol, and the Pearson correlation 
coefficient is 0.86. The largest errors are for compounds 3 and 7, but 
even these are relatively small. Perhaps most encouragingly for the 
use of FEP as a computational pre-screening tool, the three most 
potent fragments (5, 10 and 13) are in the top four computational 
predictions. 
Page 2 of 4ChemComm
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
02
 A
ug
us
t 2
01
7.
 D
ow
nl
oa
de
d 
by
 N
ew
ca
stl
e 
U
ni
ve
rs
ity
 o
n 
02
/0
8/
20
17
 1
1:
38
:3
5.
 
View Article Online
DOI: 10.1039/C7CC05379G
Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
In summary, the replica exchange with solute tempering method 
for the enhanced sampling of both protein and small molecule 
degrees of freedom has been implemented in MCPRO and used for 
the first time in FBDD to rank inhibitors of the Aurora A – TPX2 
protein-protein interaction. The utility of the method is 
demonstrated by the experimentally-verified prediction of two novel 
small-molecule inhibitors (compounds 9 and 10), one of which is as 
potent as AurkinA.18 More generally, FEP shows promise as a pre-
screening tool for use in prospective fragment-based drug design 
efforts, especially when combined with enhanced sampling of 
protein-ligand binding modes. 
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Table 1. Comparisons between computed relative free energies of 
binding (ΔΔG) and experiment.18 
 
 X Y Z ΔΔGa IC50b Kib 
1 H H H 1.05 289 62.5 
2 F H H 0.00 75.9 16.5 
3 F H F -0.94 36.0 7.8 
4 Cl H H -0.73 ND ND 
5 Cl H F -0.89 20.5 4.4 
6 Br H H -0.49 25.6 5.5 
7 CF3 H H 0.11 26.5 5.7 
8 CH3 H H 1.12 ND ND 
9 F CH3 H -0.49 42c 8.7c 
10 Br CH3 H -0.90 11.1c 2.3c 
a kcal/mol. b µM. c This work (see the ESI). 
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Figure 1. Crystal structure of AurkinA (compound 13) bound to Aurora A kinase.18 
Flexible torsional angles in the ligand (φ) and L178 on the protein (χ) are shown in red. 
 
 
Figure 2. Examples of structures sampled during MC/FEP simulations of compound 2 
bound to Aurora A. (a) φ = 180o, χ = 180o, (b) φ = 330o, χ = 180o, (c) φ = 180o, χ = 60o. 
 
 
Figure 3. Dihedral angle distributions from Monte Carlo simulations for both the phenyl 
ring of compounds 2 and 5 (φ) and the side chain of L178 (χ). Assigned dihedral angles 
from X-ray crystal structures are displayed as vertical dashed lines. 
 
Figure 4. Additional MC/FEP relative free energies of binding (kcal/mol) and 
experimental results where available.18 
 
Figure 5. Correlation between computed and experimental (= RT ln(IC50)) binding free 
energies. Computational results are offset to give the same mean as the experimental 
distribution. 
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